A5013704257- Antibiotics Pharmacokinetics and Efficacy
- Cancer therapeutics and mechanisms
- Nanoparticle-Based Drug Delivery
- Drug Transport and Resistance Mechanisms
- Cancer Treatment and Pharmacology
- Renal Transplantation Outcomes and Treatments
- Nanoplatforms for cancer theranostics
- Antibiotic Resistance in Bacteria
- Spinal Cord Injury Research
- Cancer Cells and Metastasis
- Advancements in Transdermal Drug Delivery
- Neutropenia and Cancer Infections
- Advanced Drug Delivery Systems
- Pancreatic and Hepatic Oncology Research
- Hematopoietic Stem Cell Transplantation
- Amyotrophic Lateral Sclerosis Research
- Cervical and Thoracic Myelopathy
- Radiopharmaceutical Chemistry and Applications
- Biochemical and Molecular Research
- Glioma Diagnosis and Treatment
- Pharmacogenetics and Drug Metabolism
- Plant-based Medicinal Research
- Drug Solubulity and Delivery Systems
- Cancer, Hypoxia, and Metabolism
- Neurogenetic and Muscular Disorders Research
University of Houston
2015-2024
Hong Kong Lung Foundation
2024
Rigel (United States)
2020
Texas Medical Center
1994-2018
Columbus Oncology and Hematology Associates
2016
Reckitt Benckiser (United States)
2016
University of Florida
2016
Nvidia (United States)
2010
The University of Texas MD Anderson Cancer Center
2001-2006
Christus Stehlin Foundation for Cancer Research
2005
A prospective, multicenter phase I trial was undertaken by the North American Clinical Trials Network (NACTN) to investigate pharmacokinetics and safety of, as well obtain pilot data on, effects of riluzole on neurological outcome in acute spinal cord injury (SCI). Thirty-six patients, with ASIA impairment grades A-C (28 cervical 8 thoracic) were enrolled at 6 NACTN sites between April 2010 June 2011. Patients received 50 mg PO/NG twice-daily, within 12 h SCI, for 14 days. Peak trough plasma...
Riluzole is a sodium channel-blocking agent used in treating amyotrophic lateral sclerosis. It has been approved by the U.S. Food and Drug Administration, Canadian Australian authorities, many other countries. A phase I trial of riluzole for acute spinal cord injury (SCI) provided safety pharmacokinetic data suggested neuroprotective benefits. IIB/III double-blinded randomized controlled (RCT) started January 2014 ( https://clinicaltrials.gov , NCT01597518). This article describes...
Exosomes have attracted tremendous attention due to their important role in physiology, pathology, and oncology, as well promising potential biomedical applications. Although great efforts been dedicated investigating biological properties applications natural cancer drug-delivery systems, the systemic biodistribution of exosomes remains underexplored. In addition, exosome-based drug delivery is inevitably hindered by robust liver clearance, leading suboptimal tumor retention therapeutic...
Riluzole is a sodium-glutamate antagonist that attenuates neurodegeneration in amyotrophic lateral sclerosis (ALS). It has shown favorable results promoting recovery pre-clinical models of traumatic spinal cord injury (tSCI) and early phase clinical trials. This study aimed to evaluate the efficacy safety riluzole acute cervical tSCI. An international, multi-center, prospective, randomized, double-blinded, placebo-controlled, adaptive, Phase III trial (NCT01597518) was undertaken. Patients...
The unpredictable intestinal absorption and erratic bioavailability of oral busulfan (Bu) has limited the drug's use in high-dose pretransplantation conditioning therapy. To standardize drug delivery, we solubilized Bu for parenteral use. This new intravenous (i.v.) formulation was combined with cyclophosphamide (Cy) to evaluate (1) human acute toxicity i.v. its solvent system (2) pharmacokinetics patients undergoing hematopoietic progenitor cell transplantation (HPCT). One dose (escalating...
Riluzole, a sodium/glutamate antagonist has shown promise as neuroprotective agent. It is licensed for amyotrophic lateral sclerosis and in clinical trial development spinal cord injury (SCI). This study investigated the therapeutic time-window pharmacokinetics of riluzole rodent model cervical SCI. Rats were treated with (8 mg/kg) at 1 hour (P1) 3 hours (P3) after or vehicle. Afterward, P1 P3 groups received (6 (mg/kg) every 12 7 days. Both animals had significant improvements locomotor...
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult cancers to treat. It is refractory existing therapies, including immunotherapies, due presence an excessive desmoplastic stroma, which restricts penetration drugs and cytotoxic CD8+ T cells. Stromal modulation has shown promising results in enhancement immune checkpoint blockade treatment PDAC. We demonstrate here effective stromal by a polymeric micelle-based nanoformulation codeliver sonic hedgehog inhibitor...
Object The aim of this paper was to characterize individual and population pharmacokinetics enterally administered riluzole in a Phase 1 clinical trial as neuroprotective agent adults 18–70 years old with acute spinal cord injury (SCI). Methods Thirty-five individuals SCI, American Spinal Injury Association Impairment Scale Grades A–C, neurological levels from C-4 T-12, who were enrolled the sponsored by North Clinical Trials Network for Treatment Cord Injury, received 50 mg twice daily 28...
Despite dose-limiting nephrotoxicity concerns, polymyxin B has resurged as the treatment of last resort for multidrug-resistant Gram-negative bacterial infections. However, pharmacokinetic, pharmacodynamic, and nephrotoxic properties still are not thoroughly understood. The objective this study was to provide additional insights into overall biodistribution disposition in an animal model. Sprague-Dawley rats were dosed with intravenous (3 mg/kg body weight). Drug concentrations serum, urine,...
We have investigated the folding of myosin motor domain using a chimera an embryonic striated muscle II fused on its COOH terminus to thermal stable, fast variant green fluorescent protein (GFP). In in vitro expression assays, GFP chimeric protein, S1795GFP, folds rapidly enabling us monitor fluorescence. The very slowly and transits through multiple intermediates that are detectable by gel filtration chromatography. distribution nascent among these is strongly dependent upon temperature. At...
Copper sulfide (CuS) nanoparticles have been considered one of the most clinical relevant nanosystems because their straightforward chemistry, small particle size, low toxicity, and intrinsic theranostic characteristics. In our previous studies, radioactive [64Cu]CuS were successfully developed to be used as efficient radiotracers for positron emission tomography photothermal ablation therapy cancer cells using near-infrared laser irradiation. However, major challenge CuS a platform is lack...
Doxorubicin-loaded hollow gold nanospheres (Dox@HAuNS) are a promising technology for simultaneous trans-arterial tumor-targeted chemotherapy delivery and thermal ablation. We evaluated the efficacy of intra-arterial Dox@HAuNS followed by photothermal ablation (PTA) in rabbit model liver cancer. Adult New Zealand white rabbits (N=25) were inoculated with VX2 tumors into left lobe liver. The animals then randomized to sham surgery (N=5), PTA only (N=3), HAuNS + (N=7). Nanoparticles delivered...
Twenty-five recipients of cadaveric renal transplants were given total lymphoid irradiation (TLI), perioperative antithymocyte globulin, and low-dose prednisone as the sole maintenance immunosuppressive drug. Nine patients diabetic, follow-up was between 19 37 months. One-year graft patient survival 76% 87%, respectively, Serious complications included four deaths from cardiovascular disorders, two viral infections. Studies peripheral blood T cell subsets showed a prolonged reduction in...